Lixte BiotechnologyLIXT
Market Cap: $4.48M
About: Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Employees: 4
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
1.47% more ownership
Funds ownership: 6.46% [Q1] → 7.93% (+1.47%) [Q2]
0% more funds holding
Funds holding: 6 [Q1] → 6 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
12% less capital invested
Capital invested by funds: $481K [Q1] → $424K (-$57.2K) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for LIXT.
Financial journalist opinion
Based on 3 articles about LIXT published over the past 30 days